Eloxx Pharmaceuticals (ELOX) News Today $0.70 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 11, 2024 | globenewswire.comEloxx Pharmaceuticals Provides Pipeline and Financing UpdatesApril 24, 2024 | investing.comEloxx Pharmaceuticals Inc (ELOX)April 17, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finance.yahoo.comAlport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 16, 2024 | globenewswire.comEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program UpdatesApril 5, 2024 | msn.comGene therapy and glycoside drugs offer new hope for polycystic kidney disease treatmentMarch 26, 2024 | markets.businessinsider.comNasdaq Inc. Buy Rating: EPS Growth, Valuation Expansion, and Strong FinTech ProspectsMarch 13, 2024 | finanznachrichten.deAlmirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesMarch 13, 2024 | globenewswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseasesMarch 13, 2024 | businesswire.comAlmirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological DiseasesFebruary 22, 2024 | benzinga.comEloxx Pharmaceuticals Stock (OTC:ELOX), Short Interest ReportFebruary 16, 2024 | barrons.comVertex Pharmaceuticals Inc.February 6, 2024 | finance.yahoo.comEloxx Pharmaceuticals, Inc. (ELOX)January 30, 2024 | msn.comCNS Pharmaceuticals prices $4M public offeringDecember 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)December 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Annexon Biosciences (ANNX) and United Therapeutics (UTHR)December 13, 2023 | finance.yahoo.comOff the Beaten Path: 3 Delisted Stocks for The Speculative InvestorDecember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO), Crispr Therapeutics AG (CRSP) and Biomea Fusion (BMEA)November 22, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)November 14, 2023 | msn.comHoth stock jumps on positive FDA feedback on drug HT-KITNovember 13, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business UpdateNovember 8, 2023 | morningstar.comEloxx Pharmaceuticals Inc ELOXOctober 9, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaSeptember 21, 2023 | seekingalpha.comEloxx Pharmaceuticals prices $2M stock offeringSeptember 19, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Announces Registered Direct Offering - Quick FactsSeptember 19, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesSeptember 18, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeSeptember 8, 2023 | msn.comEloxx moves ahead with plans with gene therapy for rare kidney disorderSeptember 7, 2023 | finance.yahoo.comEloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013August 30, 2023 | fool.comEloxx Pharmaceuticals (NASDAQ: ELOX)August 15, 2023 | msn.comEloxx reports all patients in Phase II Alport syndrome trial have improvedAugust 14, 2023 | markets.businessinsider.comEloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateAugust 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeAugust 14, 2023 | msn.comEloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport SyndromeAugust 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeJuly 12, 2023 | marketbeat.comThis Small Cap Stock Surged Over 100%Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer.July 11, 2023 | msn.comEloxx, Airbnb, Tesla, PainReform, Roku: Why These 5 Stocks Are Drawing Investor Attention TodayJuly 11, 2023 | benzinga.comEloxx Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 111.3%July 11, 2023 | msn.comOppenheimer Maintains Eloxx Pharmaceuticals (ELOX) Outperform RecommendationJuly 11, 2023 | marketbeat.comTrading was temporarily halted for "ELOX" at 03:07 PM with a stated reason of "LULD pause."July 11, 2023 | benzinga.comWhy Eloxx Pharmaceuticals (ELOX) Stock Is Soaring TuesdayJuly 11, 2023 | benzinga.comOppenheimer Maintains Outperform on Eloxx Pharmaceuticals, Raises Price Target to $55July 11, 2023 | marketbeat.comTrading was temporarily halted for "ELOX" at 10:07 AM with a stated reason of "LULD pause."July 11, 2023 | marketbeat.comTrading was temporarily halted for "ELOX" at 09:07 AM with a stated reason of "LULD pause."July 10, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitJune 28, 2023 | finance.yahoo.comEloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02June 21, 2023 | finance.yahoo.comEloxx Pharmaceuticals to Host Investor and Analyst Call on Alport SyndromeJune 21, 2023 | finance.yahoo.comEloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA CongressJune 15, 2023 | benzinga.comFinal Data Report: Eloxx Touts Improved Lung Function For Cystic Fibrosis CandidateJune 14, 2023 | finance.yahoo.comEloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here ELOX Media Mentions By Week ELOX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELOX News Sentiment▼0.000.62▲Average Medical News Sentiment ELOX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELOX Articles This Week▼00▲ELOX Articles Average Week Get Eloxx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TC Biopharm News Today BioCardia News Today Sorrento Therapeutics News Today Fresh Tracks Therapeutics News Today Avalon GloboCare News Today Creative Medical Technology News Today Titan Pharmaceuticals News Today Palisade Bio News Today Genetic Technologies News Today Kiromic BioPharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELOX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
